A cohort study conducted from 1976 through 2006 showed the incidence of PIDD to be 4

A cohort study conducted from 1976 through 2006 showed the incidence of PIDD to be 4.6 per 1,000,000 person-years, with rates increasing in more recent years, due to better diagnostic techniques and consciousness among medical companies.3 For individuals with significantly low immunoglobulin (Ig) production levels (IgG levels of less than 200 mg/dL), intravenous Ig (IVIG) therapy is a common and effective treatment for providing increased immunity.4 The infused antibodies that are administered by IVIG are naturally metabolized, therefore requiring repeat doses at regular intervals over a individuals lifetime.4 The benefits of IVIG Rabbit Polyclonal to E-cadherin therapy are short term, with IgG levels fluctuating from maximum to trough throughout the typical 3- to 4- week dosing interval, and the risk of infection among individuals with PIDD can still be prevalent during therapy. PIDD can have a significant impact on a individuals quality of life, as well while present a substantial economic burden to individuals and the health care system. were the most expensive component of care (US$38,574 per hospitalized patient). In multivariate modeling, the presence of a blood infection during the hospitalization (versus [vs] no blood illness), having diabetes, and more youthful age ( 18 vs 55C64) were associated with significant raises in infection-related hospitalization expenditures (49.3%, 55.3%, and 76.5%, respectively) ( em P /em 0.05). Summary Health care expenditures for infections in PIDD individuals receiving IVIG therapy can be substantial, particularly for inpatient care. Future evaluations assessing the incremental cost of optimizing IVIG therapy should include evaluation of the effects on infection-related medical expenditures. strong class=”kwd-title” Keywords: immunology, immunoglobulin alternative therapy, outcomes study, economics, treatment, source utilization Introduction Main immunodeficiency disease (PIDD) refers to a group of genetic disorders in which essential functions of an individuals immune system are intrinsically impaired. Problems can be inherent in cells such as T lymphocytes, B lymphocytes, or phagocytic cells, as a result inhibiting an individuals ability to produce antibodies or battle illness. As a result, individuals with PIDD face an increased susceptibility to illness (ie, prolonged, frequent, or uncommonly severe infections).1 Data from a telephone survey conducted from the Immune Deficiency Foundation estimate the prevalence of PIDD to be approximately one in 1,200 individuals in the United States (ie, 250,000 people).2 However, the prevalence is believed to be underestimated due to a high rate of underdiagnosis. A cohort study carried out from 1976 through 2006 showed the incidence of PIDD to be 4.6 per 1,000,000 person-years, with rates increasing in more recent years, due to better diagnostic techniques and consciousness among medical companies.3 For individuals with significantly low immunoglobulin (Ig) production levels (IgG levels of less than 200 mg/dL), intravenous Ig (IVIG) therapy is a common and effective treatment for providing increased immunity.4 The infused antibodies that are administered by IVIG are naturally metabolized, therefore requiring repeat doses at regular intervals over a individuals lifetime.4 The benefits of IVIG therapy are short term, with IgG levels fluctuating from maximum to trough throughout the typical 3- to 4- week dosing interval, and the risk of infection among individuals with PIDD can still be prevalent during therapy. PIDD can have a significant impact on a individuals quality of life, as well as present a substantial economic burden to individuals and the health care system. A survey conducted from the Jeffrey Modell Centers Network in 64 countries across six continents found that in the year prior to analysis, the average patient with undiagnosed PIDD experienced 70 physician/emergency space (ER) appointments, 19 hospitalizations, and 34 missed days of school/work annually.5 These figures improved with proper diagnosis and treatment but still offered a significant burden on patients (eg, 12 ER visits and five STA-21 hospitalizations annually with proper diagnosis and treatment). The majority of published data on the costs associated with the condition focus on the direct medical expenditures associated with Ig therapy.6,7 However, with infections becoming common among this patient population, even among those receiving IVIG therapy STA-21 (eg, over two infections per patient per year normally, with some STA-21 episodes leading to a hospitalization),8 it is important to also determine the economic burden associated with chronic infections. Published data on the cost of infections in medical practice are limited; consequently, this study set out to assess the economic effect C from the US commercial payer perspective C of infections inside a cohort of PIDD individuals who were given IVIG therapy. The findings will help to establish a more comprehensive estimate of the economic burden of PIDD to the US health care system. Methods Patient selection This retrospective database analysis used administrative medical and pharmacy statements from your Truven Health Analytics MarketScan? Commercial Study Database9 between January 1, 2008 and September 30,.